Psilocybin is a naturally-occurring psychedelic compound and the main active pharmaceutical ingredient (API) in ‘magic mushrooms.’
By activating serotonin receptors in the brain, psilocybin can significantly alter an individual’s mood, cognition, and perception. Psilocybin-producing mushrooms also contain psilocin, baeocystin, norbaeocystin, and beta-carbolines – compounds that can enhance the effect of psilocybin, in what is known as the “entourage effect.” Psilocybin has been used for thousands of years for spiritual, cultural and medicinal purposes, and is not naturally addictive.
What is Psilocybin?
There has been a renewed interest in psychedelic drugs as potential therapies for mental health conditions. Recent years have seen significant progress using psilocybin, in both clinical validation and basic research on mechanisms of change. Academic groups in United Kingdom (Imperial College; Carhart-Harris et al., 2018; 2021) and USA (John Hopkins; Griffiths et al., 2016; Johnson et al., 2014) have shown promising results in studies of synthetic psilocybin-assisted therapy on treatment-resistant depression, PTSD and addictions.
Regulatory frameworks seem to be open for approving studies, such as the recent FDA Breakthrough approvals for psilocybin to treat severe treatment-resistant depression and MDD. Although the first results from clinical research are very promising, ample work needs to be done before final conclusions on the safety and effectiveness of psilocybin-assisted therapies can be drawn. Additionally, there is a lack of development and validation of approaches aimed at optimizing the delivery of the treatments, both in terms of the psychological interventions that support the drug administration before, during and after these sessions, and measurement of treatment effects with neural and physiological data.
Our Product Development
We believe there is a need for uniquely placed natural psilocybin-based products. Zylorion has established agreements with companies dealing with the full spectrum of drug development, including production, extraction, and manufacturing, in the Netherlands, Canada and the United States. All production will be carried out under the highest GMP quality standards. We have in-house world-leading expertise in growing unique strains of psilocybin mushrooms. Our Toronto-based team holds the largest data bank of psilocybin-mushroom spores in the world. We will be focusing on the entourage effects and growing conditions, in which multiple neuroactive products will be captured, including psilocybin, psilocin, baeocystin, and norbaeocystin. These will allow unique, and IP-protected, treatment opportunities.
"After 40 years, I continue to be enthralled with the power and potential of medicinal mushrooms to heal people and our planet!"
~ Robert Rogers, author of
Psilocybin Mushrooms: The Magic, Science and Research (2021)
"Having now studied mushrooms and medicinal fungi for the past 28 years, it is exciting to be
a part of a movement that is now becoming
a paradigm shift on many fronts.
There are so many gifts that fungi offer to humanity and the planet as a whole: food,
fuel, building materials, medicines, we are
just now seeing the tip of the iceberg
and the possibility of infinite solutions! "
~ Tradd Cotter (2021)